Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

symptoms

- PMLiVE

Revlimid performance leads Celgene to trio of PMEAs

Wins Small Company of the Year thanks to work on rare cancer drug

Celgene poaches Sanofi Pasteur’s medical director

Adrian Kilcoyne announced as David Gillen’s replacement

- PMLiVE

Psoriasis care falling short says Janssen survey

Claims dermatologists in UK are failing to refer to recommended clinical guidelines

- PMLiVE

Celgene lifted by apremilast data in psoriatic arthritis

Long-term data keeps marketing application plans on course

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

- PMLiVE

Baxter taps Coherus for Enbrel biosimilar

Deal to develop copy of Amgen and Pfizer's arthritis and psoriasis is worth up to $246m

EU flag

Europe backs two blood cancer treatments

Approvals for J&J’s Velcade and Celgene’s Imnovid for treatment of multiple myeloma

- PMLiVE

Celgene halts Revlimid trial after patient deaths

High mortality rate in trial involving elderly patients with rare leukaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links